Strontium ranelate

Status : approved

Therapeutic Classification

DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION

MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION

Description

Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a “dual action bone agent” (DABA).

Used

For the treatment of osteoporosis.

Chemical Classification

This compound belongs to the class of organic compounds known as glycine and derivatives. These are compounds containing glycine or a derivative thereof resulting from reaction of glycine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.

Glycine and derivatives

Organic compounds

Organic acids and derivatives

Carboxylic acids and derivatives

Amino acids, peptides, and analogues

Calculated Property

kind Value Source
Molecular Weight 513.49 ChemAxon
Monoisotopic Weight 513.795712 ChemAxon
SMILES [Sr++].[Sr++].[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O ChemAxon
Molecular Formula C12H6N2O8SSr2 ChemAxon
InChI InChI=1S/C12H10N2O8S.2Sr/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20;;/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22);;/q;2*+2/p-4 ChemAxon
InChIKey XXUZFRDUEGQHOV-UHFFFAOYSA-J ChemAxon